One additional thought to potential newco valuation. Since the cash portion alone of the Tensha deal values a phase 1 BET inhibitor at 115 million USD that would support Don's thoughts that the newco alone, once in phase 1 will be worth better than $1USD per share. I think this is further supported by RVX going into phase 1 with what Don said is a 3rd generation BET inhibitor where everyone else is either 1st or 2nd generation (this should be on the posted company presentation) and many of the others are based on benzodiazepine scaffolds which apparently have cardiovascular related issues. I am a little fuzzy on the distinction between 1st, 2nd and 3rd generation but this was part of Don's discussion as to why Zenith/newco would be passing the competition within 6 months with respect to program development. Perhaps Bear or someone else could shed more light on the "generational" distinctions.